- 基本信息
|
导师姓名：
|
谢青
|
学科代码：
|
100201
|
|
|
性别：
|
女
|
学科名称：
|
内科学
|
|
培养单位：
|
附属瑞金医院
|
三级学科
|
传染病
|
|
导师类型：
|
博士生导师
|
专业领域名称：
|
内科学 专业学位
|
|
联系方式：
|
上海瑞金二路197号瑞金医院36号楼，感染科
|
专业领域代码：
|
105101
|
|
邮编：
|
200025
|
邮箱地址：
|
xieqingrjh@163.com
|
- 研究方向 (点击浏览详细信息)
- 社会任职
| |
|
中华传染病杂志副总编辑
|
|
上海医师协会感染科医师分会会长
|
|
中国医师协会感染科医师分会副会长
|
|
上海市感染性疾病临床质量控制中心主任
|
|
中华医学会感染病分会副主任委员
|
|
上海市医学会医疗事故技术鉴定专家库成员
|
|
卫生部国家医学继续教育委员会委员
|
|
中华医学会肝病学分会病毒性肝炎学组副组长
|
|
国家食品药品监督局新药评审中心评审专家
|
|
上海市医学会肝病学分会副主任委员
|
|
第八届上海医学会感染病分会主任委员
|
|
《肝脏》杂志副主编
|
|
上海市医学会内科学分会副主任委员
|
|
中华医学会感染病分会产科感染与肝病学组组长
|
|
上海市医院协会传染病专科医院管理委员会副主任委员
|
|
上海市“感染性疾病科临床质量控制中心”主任
|
|
中华肝脏病杂志编委
|
- 科研项目
| 82070604 | 药物诱导的胆汁淤积中FABP4通过SphK-S1P信号通路对肝细胞损伤及适应性保护的作用及分子机制研究 | 国家自然科学基金 |
2021-01~2024-12
|
56万元
| 课题负责人 |
| IN-CN-174-5648 | Risk of Hepatocellular Carcinoma in Patients Treated with ETV vs TDF for Chronic Hepatitis B with Compensated Cirrhosis | Glead Science.Inc |
2019-08~2020-09
|
106.97万元
| 课题负责人 |
| IN-CN-342-5424 | Effectiveness, safety of DAAs therapy in HCV infection: Results from a EAST China real world cohort | Glead Science.Inc |
2019-01~2020-09
|
392.28万元
| 课题负责人 |
| 2018CR005 | 聚乙二醇干扰素a-2b降低肝癌高风险的慢性乙型肝炎患者肝癌风险的一项前瞻、随机、开放、多中心的研究 | 上海瑞金医院 |
2019-01~2021-12
|
180万元
| 课题负责人 |
| shslczdzk01103 | 上海市临床重点专科（感染病学-振龙头项目) | 上海卫健委 |
2019-01~2021-12
|
1089万元
| 课题负责人 |
| 00000 | infections and other complications of cirrhosis: a prospective multi-center study | 上海交通大学医学院2018年国际及港澳地区国际合作项目 |
2018-01~2019-12
|
15万元
| 课题负责人 |
| 81770587 | IL-22介导自噬信号通路抑制NLRP3炎性小体活化在药物性肝损伤中发挥肝保护效应的作用及机制研究 | 国家自然基金（面上） |
2018-01~2021-12
|
56万元
| 课题负责人 |
| 2018ZX09206005-004 | 2018ZX09206005-004 | 国家科技部十三五重大专项 |
2018-01~2021-12
|
80万元
| 子课题负责人 |
| 2017ZX10202202-005-004 | 乙型肝炎联合治疗新方案对疾病远期转归的影响 | 国际科技部十三五重大专项 |
2017-01~2020-12
|
107万元
| 子课题负责人 |
| 2017ZX10203201-008 | 重型乙型肝炎（肝衰竭）诊治新技术新方案研究-细菌感染诊治对预后转归影响的研究 | 国家科技部十三五重大专项 |
2017-01~2020-12
|
54.48万元
| 子课题负责人 |
| 16CR1002A | 应用RGT(Response-GuidedTherapy)策略对HBeAg阳性慢性乙型肝炎患者使用核苷类似物后联合使用聚乙二醇干扰素a-2a的有效性和安全性的前瞻、随机、开放、多中心研究 | 第一轮促进市级医院临床技能与临床创新三年行动计划 |
2016-12~2019-06
|
200万元
| 课题负责人 |
| 81570535 | IL-22在药物性肝损中抑制氧应激诱导的炎症反应发挥肝保护效应的作用及机制研究 | 国家自然基金（面上） |
2016-01~2019-10
|
79.2万元
| 课题负责人 |
| 16 | 重型乙型肝炎（肝衰竭）临床治疗新方案的研究-规范化抗病毒治疗对重型乙型肝炎长期临床结局的影响及各类并发症早期诊断和干预策略 | 市人力资源和社会保障局（上海领军人才队伍建设专项资金资助）中期考核优秀追加经费 |
2015-01~2016-12
|
15万元
| 课题负责人 |
| 15GWZK0102 | 上海市公共卫生三年行动计划重点学科建设项目传染病与卫生微生物学 | 上海市卫计委 |
2015-01~2017-12
|
750万元
| 课题负责人 |
| 2014ZX10005001 | 中医药联合恩替卡韦治疗乙肝肝硬化的临床研究 | “艾滋病和病毒性肝炎等重大传染病防治”国家科技重大专项 |
2014-01~2016-12
|
77.5万元
| 子课题负责人 |
| 134119a2401 | 药物性肝损伤临床诊断评分系统的建立和应用 | 上海市科委（医学引导） |
2013-06~2016-06
|
30万元
| 课题负责人 |
- 学术论文
|
Jie Lu*,Qing Li*,Jiayuan Jiang*,Ziqiang Li,Peiyun Wang,Zike Sheng,Rongtao Lai,Huijuan Zhou,Wei Cai,Hui Wang,Qing Guo*,Honglian Gui*,
|
Laboratory-based Surveillance and Clinical Profile of Sporadic HEV Infection in Shanghai, China
|
Virologica Sinica
|
2021
|
10.1007/s12250-020-00336-w
|
|
Qinyi Gan?, Beilei Gong? , Manli Sun?, Zhujun Cao , Yuyan Zheng , Yajie Zhang, Pengfei Wen , Yuanbing Shen, Lei Hong, Tingting Hou, Yuqin Jia*? , Wei Li*?, Hecheng Li*? and Qing Xie*
|
A High Percentage of Patients Recovered From COVID-19 but Discharged With Abnormal Liver Function Tests
|
Frontiers in Physiology
|
2021
|
12:642922.doi: 10.3389
|
|
Rongtao Lai*, Tianhui Zhou*, Xiaogang Xiang, Jie Lu, Haiguang Xin*,
|
Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections
|
Frontiers of Medicine
|
2021
|
1-5
|
|
Jie Lu*, Yan Huang*, Peiyun Wang, Qing Li, Ziqiang Li, Jiayuan Jiang, Qing Guo, Honglian Gui*,
|
Dynamics of Hepatitis E Virus (HEV) Antibodies and Development of a Multifactorial Model To Improve the Diagnosis of HEV Infection in Resource-Limited Settings
|
Journal of Clinical Microbiology
|
2021
|
59 ( 2): e02321-20
|
|
Honglian Gui#,Weijing Wang#,Qing Li, Ziqiang Li,Jie Lu#,
|
Autoimmune liver disease-associated serologic profiling in Chinese patients with acute hepatitis E virus infection
|
Immunologic Research
|
2021
|
1
|
|
Acute-on-chronic liver failure in East Asia: an underestimated issue with limited data
|
Acute-on-chronic liver failure in East Asia: an underestimated issue with limited data
|
Gut
|
2021
|
1
|
|
Honglian Gui ??, Yan Huang? , Gangde Zhao, Lichang Chen, Wei Cai, Hui Wang, Qing Guo*
and Qing Xie*?
|
External Validation of aMAP Hepatocellular Carcinoma Risk Score in Patients With Chronic Hepatitis B-Related Cirrhosis Receiving ETV or TDF Therapy
|
Front. Med
|
2021
|
1
|
|
Xiaolin Wang, Lu Chen, Hui Wang*, Wei Cai*,
|
Modulation of bile acid profile by gut microbiota in chronic hepatitis B
|
J Cell Mol Med.
|
2020
|
24:2573–2581
|
|
Lu Chen*, Lanyi Lin*, Huijuan Zhou, Weiliang Tang, Hui Wang, Wei Cai, Shisan Bao*, Simin Guo*,
|
Peginterferon and Entecavir Combination Therapy Improves Outcome of Non–Early Response Hepatitis B e Antigen–Positive Patients
|
Open Forum Infectious Diseases
|
2020
|
7(11):ofaa462.doi
|
|
Fan R, Zhou B, Xu M, Tan D, Niu J, Wang H, Ren H, Chen X, Wang M, Ning Q, Shi G, Sheng J, Tang H, Bai X, Liu S, Lu F, Peng J, Sun J,, Hou J*
|
Chronic Hepatitis B Study Consortium. Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucles(t)ide Analogue Therapy.
|
Clin Gastroenterol Hepatol.
|
2020
|
18(3):719-727
|
|
Zhujun Cao, Yuhan Liu, Minghao Cai, Yumin Xu, Xiaogang Xiang, Gangde Zhao, Wei Cai,Hui Wang, Weijing Wang,
|
The Use of NACSELD and EASL-CLIF Classification Systems of ACLF in the Prediction of Prognosis in Hospitalized Patients With Cirrhosis
|
Am J Gastroenterol
|
2020
|
accept
|
|
Zhu-Jun Cao*, Yu-Han Liu*, Chuan-Wu Zhu*, Shan Yin, Wei-Jing Wang, Wei-Liang Tang, Gang-De Zhao, Yu-Min Xu, Lu Chen, Tian-Hui Zhou, Ming-Hao Cai, Hui Wang, Wei Cai, Shi-San Bao*, Hai Li*,
|
Bacterial infection triggers and complicates acute-on-chronic liver failure in patients with hepatitis B virus-decompensated cirrhosis: a retrospective cohort study
|
World J Gastroenterol.
|
2020
|
26(6):645-656
|
|
Hong-lian Gui#, Chang-qing Zhao#, Yan Wang , Hong-tu Gu , Wei-jing Wang, Wei Cai, Qing Guo , Shi-san Bao , Lie-ming Xu* and Qing Xie*
|
Histological Outcome of Fuzheng Huayu plus Entecavir Combination Therapy in Chronic Hepatitis B Patients with Significant Liver Fibrosis
|
Journal of Clinical and Translational Hepatology
|
2020
|
vol. 8: 1–8
|
|
Wei Tang,Zhujun Cao, Mingfeng Han, Zhengyan Wang, Junwen Chen, Wenjin Sun, Yaojie Wu, Wei Xiao, Shengyong Liu, Erzhen Chen, Wei Chen, Xiongbiao Wang, Jiuyong Yang, Jun Lin, Qingxia Zhao, Youqin Yan, Zhibin Xie, Dan Li, Yaofeng Yang, Leshan Liu, Jieming Qu, Guang Ning, Guochao Shi,
|
Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial
|
BMJ
|
2020
|
May 14;369:m1849. doi: 10.1136/bmj.m1849.
|
|
Zhujun Cao , Yuhan Liu, Shijin Wang, Xiaobo Lu, Shan Yin, Shaowen Jiang, Liuying Chen, Minghao Cai, Bo Zeng, Yujing Yao, Weiliang Tang, Gangde Zhao,, Hui Wang, Wei Cai, Chuanwu Zhu, Hai Li, Qing Xie
|
The Impact of HBV Flare on The Outcome of HBV-related Decompensated Cirrhosis Patients with Bacterial Infection
|
Liver Int.?2019 Oct;39(10):1943-1953
|
2019
|
39(10):1943-1953
|
|
Fan R,Zhou B,Xu M,Tan D,Niu J,Wang H,Ren H,Chen X,Wang M,Ning Q,Shi G,Sheng J,Tang H,Bai X,Liu S,Lu F,Peng J,Sun J,,Hou J
|
Chronic Hepatitis B Study Consortium.Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucles(t)ide Analogue Therapy
|
Clin Gastroenterol Hepatol
|
2019
|
3565(19)30790-6
|
|
Yumin Xu, Zhujun Cao, Yezhou Ding , Ziqiang Li, Xiaogang Xiang, Rongtao Lai, Zike Sheng , Yuhan Liu , Wei Cai , Ronggui Hu, Hui Wang and Qing Xie
|
Long Non-coding RNA NEAT1 Alleviates Acute-on-Chronic Liver Failure Through Blocking TRAF6 Mediated Inflammatory Response
|
Frontiers in Physiology
|
2019
|
10：1503
|
|
, Jian-Wei Xuan, Hong Tang, Xiao-Guang Ye, Peng Xu, I-Heng Lee, Shan-Lian Hu
|
Hepatitis C virus cure with direct acting antivirals: Clinical, economic, societal and patient value for China
|
World J Hepatol
|
2019
|
11(5): 421-441
|
|
Jie Lu?, Yupeng Feng?, Lichang Chen?, Zhengyu Zeng, Xianliang Liu, Wei Cai,Hui Wang, Xiaolei Guo, Huijuan Zhou*, Wanyin Tao* and Qing Xie*
|
Subtype-Specific Prevalence of Hepatitis C Virus NS5A Resistance Associated Substitutions in Mainland China
|
Subtype-Specific Prevalence of Hepatitis C Virus NS5A Resistance Associated Substitutions in Mainland China
|
2019
|
10:535
|
|
Yumin Xu, Yuhan Liu, Zhujun Cao, LinWanga, Ziqiang Li , Zike Sheng,Wei Cai,
Hui Wang, Shisan Bao,
|
Comparison of FibroTouch and FibroScan for staging fibrosis in chronic liver disease: Single-center prospective study
|
Dig?Liver?Dis
|
2019
|
51(9):1323-1329
|
|
Xiaogang Xiang, Dechun Feng, Seonghwan Hwang, Tianyi Ren, Xiaolin Wang, Eszter Trojnar, Csaba Matyas, Ruidong Mo, Dabao Shang,, Wonhyo Seo, Vijay H. Shah, Pal Pacher, Qing Xie,* Bin Gao*
|
Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming of impaired regeneration pathway
|
J Hepatology, 2019, Nov 29
|
2019
|
72(4):736-745
|
|
Zhujun Cao; Liwen Chen; Jing Li; Yuhan Liu; Rebecca Bao; Kehui Liu; Lei Yan; Yezhou Ding; Qing Guo; Xiaogang Xiang; Jingdong Xie; Lanyi Lin; Qing Xie; Shisan Bao; Hui Wang
|
Serum keratin-18 fragments as cell death biomarker in association with disease progression and prognosis in cirrhosis with HBV infection.
|
J of viral hepatitis
|
2019
|
26(7):835-845
|
|
Rui Yu, Deming Tan,Qin Ning, Junqi Niu, Xuefan Bai,Shijun Chen,Jun Cheng,
Yanyan Yu,Hao Wang,Min Xu,Guangfeng Shi, Mobin Wan, Xinyue Chen,Hong Tang, Jifang Sheng, Xiaoguang Dou,Junping Shi, Hong Ren,MaorongWang,Hongfei Zhang, Zhiliang Gao,Chengwei Chen, Hong Ma, Jidong Jia,,
Qing Xie and Jian Sun
|
Association of baseline vitamin D level with genetic
|
Hepatology Research
|
2018
|
48: E213–E221
|
|
Tianhui Zhou, Ye Sun, Ming Li, Yongsen Ding, Rongkun Yin, Ziqiang Li,, Shisan Bao and Wei Cai
|
Enhancer of zeste homolog 2-catalysed H3K27 trimethylation plays a key role in acute-on-chronic liver failure via TNF-mediated pathway
|
Cell Death and Disease
|
2018
|
9:590
|
|
Ruidong Mo, Rongtao Lai1, Jie Lu1, Yan Zhuang, Tianhui Zhou, Shaowen Jiang1, Peipei Ren,
Ziqiang Li, Zhujun Cao, Yuhan Liu, Lichang Chen, Lifu Xiong, Peng Wang, Hui Wang, Wei
Cai, Xiaogang Xiang, Shisan Bao,
|
Enhanced autophagy contributes to protective effects of
|
Theranostics
|
2018
|
8(15): 4170-4180
|
|
Heng Chi, Bettina E. Hansen, Simin Guo, Ning Ping Zhang, Xun Qi, Liang Chen, Qing Guo, Pauline Arends, Ji-Yao Wang, Elke Verhey,Robert J. de Knegt,, and Harry L. A. Janssen
|
Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON)
|
The Journal of Infectious Diseases
|
2017
|
215:1085-1093
|
|
Lu J, Xiang X, Cao Z, Wang W, Zhao G, Tang W, Chen L, Guo S, Zhuang Y, Shi D, Chen L, Bao S, Cai W, Wang H, Zhou H,
|
Younger trend of cirrhosis incidence in genotype 3 HCV infected patients in Eastern China.
|
J Med Virol
|
2017
|
89 (11):1973-1980
|
|
Mo R, Wang P, Lai R, Li F, Liu Y, Jiang S, Zhao G, Guo S, Zhou H, Lin L, Lu J, Cai W, Wang H, Yu H, Bao S, Xiang X,
|
Persistently elevated circulating Th22 reversely correlates with prognosis in HBV-related acute-on-chronic liver failure.
|
J Gastroenterol Hepatol
|
2017
|
32(3):677-686
|
|
Jiang SW, Wang P, Xiang XG, Mo RD, Lin LY, Bao SS, Lu J,
|
Serum soluble ST2 is a promising prognostic biomarker in HBV-related acute-on-chronic liver failure. Hepatobiliary Pancreat Dis Int. 2017 Apr;16(2):181-188.
|
Hepatobiliary Pancreat Dis Int
|
2017
|
16(2):181-188
|
|
Cao Z, Li Z, Wang H, Liu Y, Xu Y, Mo R, Ren P, Chen L, Lu J, Li H, Zhuang Y, Liu Y, Wang X, Zhao G, Tang W, Xiang X, Cai W, Liu L, Bao S,
|
Algorithm of Golgi protein 73 and liver stiffness accurately diagnoses significant fibrosis in chronic HBV infection
|
Liver Int
|
2017
|
37 (11):1612-1621
|
|
Cao Z, Li Z, Wang Y, Liu Y, Mo R, Ren P, Chen L, Lu J, Li H, Zhuang Y, Liu Y, Wang X, Zhao G, Tang W, Xiang X, Wang H, Cai W, Liu L, Zhu C, Bao S,
|
Assessment of serum Golgi protein 73 as a biomarker for the diagnosis of significant fibrosis in patients with chronic HBV infection.
|
J Viral Hepat
|
2017
|
Suppl 1:57-65
|
|
Liu Y, Yu F, Han Y, Li Q, Cao Z, Xiang X, Jiang S, Wang X, Lu J, Lai R, Wang H, Cai W, Bao S,
|
SUMO-specific protease 3 is a key regulator for hepatic lipid metabolism in non-alcoholic fatty liver disease. Sci Rep 2016 Nov 17, 6:37351.
|
Sci Rep
|
2016
|
6:37351
|
|
Wang WJ, Lai RT, Lu J, Xiang XG, Zhao GD, Tang WL, Cai W, Wang H, Zhou HJ,
|
Correlation between circulating miR-122 and prognosis of chronic HBV-related liver failure
|
J Dig Dis
|
2016
|
17 (5):334-339.
|
|
Zhuang Y, Li Y, Li X,, Wu M.
|
Atg7 Knockdown Augments Concanavalin A-Induced Acute Hepatitis through an ROS-Mediated p38/MAPK Pathway
|
PLoS One.
|
2016
|
11(3):e0149754
|
|